GV-58 is a Roscovitine (Cat. No. 1950) derivative that acts as a selective N- and P/Q-type Ca²⁺-channel agonist. These Ca2²⁺-channels regulate transmitter release in synapses. Potential lead compound for a variety of disorders that result in neuromuscular weakness.